BLT - Probi announces new representative for Blis Board

Tuesday 20th December 2022

Blis Technologies Limited (NZX: BLT ) advises the appointment of Dr Jörn Andreas as a director of the company with effect from 1 January 2023. Dr Andreas will replace Tom Rönnlund who is retiring from the board following stepping down as CEO of Probi AB earlier this month.

Dr Andreas has been a director of Probi AB since 2019 and is CEO of the Cosmetic Ingredients Division at Symrise . He also has experience from both a previous assignment as board member (2014-2016) at Probi and his position as CFO of the company (2017-2018).

He has extensive international experience working at Symrise in France and USA in different finance and general management roles. Jörn has also worked for The Boston Consulting Group and Bayer AG in Germany.

The board has determined that Dr Andreas is not an independent director due to his role as a director of Probi AB, which is a substantial product holder of Blis Technologies. Dr Andreas will formally offer himself for re-election as director at the 2023 shareholders’ meeting.

Chairman Geoff Plunket said “We are delighted to have Jörn joining the board. Jörn has extensive commercial experience in senior executive and board roles that will complement our refocused strategy. His experience with both Probi and Symrise provides insight across a significant cross section of ingredient markets globally.”

I also wish to acknowledge the contribution Tom has made during his time on the board. He has provided valuable insights into the probiotic market and been pivotal in his role as Probi CEO in establishing a strong working relationship between the Blis and Probi teams.

Ends

Probi announces new representative for Blis Board

Comments from our readers

No comments yet